Four-hundred and nine patients with metastatic melanoma or renal cancers were treated with a high dose of IL-2 (720,000 IU/kg) between September 1985 and November 1996 with a median potential follow-up of 7.1 years. This evidence concerns the gene IL2 and metastatic melanoma.